Exhibit 99.1
TEVA ANNOUNCES CHANGES TO EXECUTIVE
MANAGEMENT TEAM
TEL AVIV, Israel & PARSIPPANY, N.J., September 28, 2023 Teva Pharmaceutical Industries Ltd. (NYSE and TASE:
TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene
Therapies at Novartis will be the new head of Tevas U.S. Commercial Business. On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with
the company, said Richard Francis, Tevas President, and Chief Executive Officer, I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a heralded pharmaceutical executive with extensive experience
growing and overseeing complex business units and regional operations throughout the world. I have every confidence that Chris will bring great strength to Teva and be pivotal to our success.
Biography: Christine Fox
Christine (Chris) Fox comes to
Teva as Executive Vice President, U.S. Commercial Business from her role at Novartis Gene Therapies where she started as President in December 2021. Prior to this role, Chris was vice president and general manager for the Bone, Cardiometabolic and
Nephrology business for Amgen. She also served as the general manager of the companys United Kingdom and Ireland affiliate. Earlier in her career, she also held leadership positions at Merck, Takeda, and several startups.
Chris brings more than 30 years of healthcare industry experience with leadership roles in sales, marketing, and commercial operations, responsible for teams
ranging from 2500+ associates to small, nimble consulting teams. She has a deep understanding of issues affecting the pharmaceutical and biotech sectors, as well as expertise across a range of therapy areas.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic
area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have
significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on managements current beliefs and expectations and are subject to substantial risks and uncertainties, both known and
unknown, that could cause our future results, performance, or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as
should, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe and other words and terms
of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our business and operations in general,
including our ability to attract, hire, integrate
|
|
|
|
|
|
|
IR Contacts |
|
United States |
|
Ran Meir |
|
(267) 468-4475 |
|
|
|
|
Sanjeev Sharma |
|
(93) 524-1908 |
|
|
|
|
PR Contacts |
|
United States |
|
Kelley Dougherty |
|
(973) 658-0237 |
|
|
|
|
Yonatan Beker |
|
(973) 264 7378 |